ALB and chronic kidney disease: FIGARO-DKD [116] was a clinical study evaluating finerenone in 7437 patients with CKD (eGFR 25–90 mL/min/1.73 m2 and urinary albumin excretion 30 -< 300 mg/g or patients with urinary albumin excretion 300–5000 mg/g and eGFR ≥ 60 mL/min/1.73 m2) and T2DM.